PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company’s Ongoing D-PLEX₁₀₀ Phase 3 Trial

Rhea-AI Summary

PolyPid announced a virtual Key Opinion Leader (KOL) event on June 17, 2024, at 10:00 AM ET to discuss the unmet medical need in surgical site infections (SSIs). Charles E. Edmiston, Ph.D., an Emeritus Professor of Surgery at the Medical College of Wisconsin, will highlight the clinical and economic burden of SSIs and current practices for their prevention. The event will also provide an update on PolyPid's Phase 3 SHIELD II trial for D-PLEX100, a product aimed at preventing abdominal colorectal SSIs. During the event, PolyPid management will update on patient enrollment status. A live Q&A session with Professor Edmiston and the management team will follow.

Positive

• PolyPid is actively addressing an unmet medical need in surgical site infections (SSIs).
• The event features a respected expert, Charles E. Edmiston, Ph.D., lending credibility.
• Phase 3 SHIELD II trial for D-PLEX100 progresses, indicating advancements in their pipeline.
• Management will update on patient enrollment, providing transparency and progress tracking.

Negative

• No new clinical data or trial results will be presented at the event.
• Event focus on an ongoing trial may indicate delays or slow progress in other areas.
• Absence of financial performance updates or revenue projections is a notable omission.

• Charles E. Edmiston, Ph.D., Emeritus Professor of Surgery, Medical College of Wisconsin, to discuss the significant unmet medical need in surgical site infections prevention
• Company to Provide an Update on SHIELD II Phase 3 Study Enrollment During Event
  

PETACH TIKVA, Israel, June 10, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a virtual Key Opinion Leader (KOL) event on Monday, June 17, 2024, at 10:00 AM ET, to discuss the significant unmet medical need in surgical site infections and provide an update on the Company’s ongoing D-PLEX₁₀₀ Phase 3 trial. To register, click here.

The event will feature Charles E. Edmiston, Ph.D. (Emeritus Professor of Surgery, Division of Vascular Surgery, Medical College of Wisconsin), who will discuss the significant clinical and economic burden, and current medical practice, for the prevention of surgical site infections (SSIs). It will also highlight PolyPid's lead product candidate, D-PLEX₁₀₀, and its ongoing Phase 3 SHIELD II trial evaluating D-PLEX₁₀₀ for the prevention of abdominal colorectal SSIs. PolyPid management intends to provide an update on patient enrollment in SHIELD II during the event.

A live question and answer session with Professor Edmiston and the Company’s management team will follow the formal presentation.

About Charles E. Edmiston, Ph.D.

Charles E. Edmiston, Ph.D., is Emeritus Professor of Surgery, at the Medical College of Wisconsin in Milwaukee, Wisconsin, where he also served as Director and Professor, Surgical Microbiology and Hospital Epidemiology Research Laboratory, and Hospital Epidemiologist, Froedtert Hospital. Dr. Edmiston served as Adjunct Professor, Vanderbilt University School of Medicine, Nashville, Tennessee, and SSI Expert Liaison for the State of Wisconsin Division of Public Health. He completed his doctorate at Vanderbilt University in Nashville, Tennessee, joining the Surgical faculty in Milwaukee in 1984 to develop a surgical infectious disease research program.

Professor Edmiston is a fellow of the Infectious Disease Society of American, Association of Practitioners in Infection control and Epidemiology, Surgical Infection Society and Society for Healthcare Epidemiology of America. He is board credentialed in both Infection Control (CBIC) and as a Specialist in Clinical Microbiology (ASCP) and has served as a consultant to the U.S. Food and Drug Administration (FDA) as an expert on the infection control implications of implantable biomedical devices, including as Chairman of the General Hospital and Personal Use Device Panel of the Medical Devices Committee of the FDA. Dr. Edmiston has also served as Surgical Infection Society (SIS) liaison to the Hospital Infection Control Practice Advisory Committee (HICPAC) of the Centers for Disease Control and Prevention (CDC).

Dr. Edmiston is a current member of two Editorial Boards: Infection Control and Hospital Epidemiology, and Surgical Infections, and a past board member of Surgery, American Journal of Infection Control and JAMA Surgery. His major research interests include intravascular device-related infections, nosocomial risks in the operating room environment, biomedical-device associated infections, impact of selected risk factors for SSIs, perioperative antibiotic prophylaxis, surface disinfection, innovative strategies for reducing the risk of SSIs, molecular epidemiology of SSIs and perioperative antisepsis. Dr. Edmiston is the author of over 400 published peer-reviewed publications including book chapters, editorials reviews, manuals and abstracts, and has delivered over 500 national and international invited lectures/workshops.

About SHIELD II

SHIELD II (Surgical site Hospital acquired Infection prEvention with Local D-PLEX) is a prospective, multinational, randomized, double blind Phase 3 trial designed to assess the efficacy and safety of D-PLEX₁₀₀ administered concomitantly with standard of care (SoC), which includes prophylactic systemic antibiotics, compared to SoC alone arm, in the prevention of post abdominal-surgery incisional infection in patients undergoing abdominal colorectal surgeries with large incisions. The primary endpoint of the trial is measured by the proportion of subjects with either a SSI event as determined by a blinded and independent adjudication committee, reintervention, or mortality for any reason within 30 days post-surgery. Patient safety will be monitored for an additional 30 days. The trial will enroll patients in centers in the United States, Europe and Israel.

About D-PLEX₁₀₀

D-PLEX₁₀₀, PolyPid’s lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX₁₀₀ into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX₁₀₀ received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the prevention of SSIs in patients undergoing elective colorectal surgery. D-PLEX₁₀₀ is currently in Phase 3 SHIELD II trial for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com

FAQ

When is the PolyPid virtual KOL event for D-PLEX100?

The event will be held on June 17, 2024, at 10:00 AM ET.

What will be discussed during PolyPid's KOL event?

The event will discuss the unmet medical need in preventing surgical site infections and provide an update on the SHIELD II Phase 3 trial for D-PLEX100.

Who will be speaking at PolyPid's KOL event?

Charles E. Edmiston, Ph.D., an Emeritus Professor of Surgery, will discuss the clinical and economic burden of SSIs.

What is D-PLEX100?

D-PLEX100 is PolyPid's lead product candidate aimed at preventing abdominal colorectal surgical site infections.

What trial updates will PolyPid provide during the event?

PolyPid will update on patient enrollment in the SHIELD II Phase 3 trial.